



## Advancing Pharmacogenetics in Pre-clinical Research: Unveiling New Avenues for Precision Medicine

Guest Editors:

**Dr. Miriam Saiz-Rodriguez**

Research Unit, Fundación Burgos  
por la Investigación de la Salud  
(FBIS), Hospital Universitario de  
Burgos, 09006 Burgos, Spain

**Dr. Shengying Qin**

Bio-X Institutes, Shanghai  
Jiaotong University, Shanghai,  
China

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editors

Pharmacogenetics tailors medical treatments based on individual genetic variations, optimizing drug response, efficacy and safety. Pre-clinical research forms the foundation for translating these findings into clinical practice. This issue aims to explore the latest discoveries in pharmacogenetics, with a focus on pre-clinical research and its impact on precision medicine.

We welcome original research articles and reviews on various aspects of pharmacogenetics in pre-clinical research, including genetic variant identification, mechanistic insights, novel models and methodologies, integrating pharmacogenetic data in drug development and translational challenges. We invite your contributions to advance our understanding of pharmacogenetics and shape personalized therapeutics.

Please, refer to the journal's submission guidelines for manuscript preparation and submission instructions. Contact us with any queries or for further information. Join us in uncovering new avenues for precision medicine!





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)